



Europäisches Patentamt  
European Patent Office  
Office européen des brevets



(11) **EP 0 966 967 A2**

(12) **EUROPEAN PATENT APPLICATION**

(43) Date of publication:  
29.12.1999 Bulletin 1999/52

(51) Int Cl.<sup>6</sup> **A61K 31/55, A61K 31/135,  
A61K 33/00, A61K 31/19,  
A61K 31/195**

(21) Application number: **99303968.4**

(22) Date of filing: **21.05.1999**

(84) Designated Contracting States:  
**AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU  
MC NL PT SE**  
Designated Extension States:  
**AL LT LV MK RO SI**

(72) Inventor: **Tollefson, Gary Dennis**  
Indianapolis, Indiana 46236 (US)

(30) Priority: **29.05.1998 US 87126 P**

(74) Representative: **Hudson, Christopher Mark et al**  
**Eli Lilly and Company Limited,**  
**Lilly Research Centre,**  
**Erl Wood Manor**  
**Windlesham Surrey GU20 6PH (GB)**

(71) Applicant: **ELI LILLY AND COMPANY**  
Indianapolis, Indiana 46285 (US)

(54) **Combination therapy of olanzapine (zyprexa) and fluoxetine (prozac) for treatment of bipolar disorder**

(57) The invention provides methods and compositions for the treatment of Bipolar Disorder, Bipolar Depression or Unipolar Depression, all with or without psy-

chotic features. This method employs a compound having activity as an atypical antipsychotic and a serotonin reuptake inhibitor.

**EP 0 966 967 A2**

## Description

[0001] The present invention belongs to the fields of pharmacology, medicine and medicinal chemistry, and provides methods and compositions for treating Bipolar Disorder, Bipolar Depression or Unipolar Depression.

[0002] Bipolar Disorder is a psychiatric condition which is prevalent across cultures and age groups. The lifetime prevalence of Bipolar Disorder can be as high as 1.6%. DSM-IV, p. 353 (American Psychiatric Association, Washington, D.C. 1997). Bipolar Disorder is a recurrent disorder characterized by one or more Manic Episodes immediately before or after a Major Depressive Episode or may be characterized by one or more Major Depressive Episodes accompanied by at least one Hypomanic Episode. Additionally, the symptoms must cause clinically significant distress or impairment in social, occupational, or other important areas of functioning.

[0003] In some cases the Hypomanic Episodes themselves do not cause impairment; however, the impairment may result from the Major Depressive Episodes or from a chronic pattern of unpredictable mood episodes and fluctuating unreliable interpersonal and occupational functioning. The symptoms of Bipolar Disorder must not be better accounted for by a psychotic condition or due to the direct physiological effects of a medication, other somatic treatments for depression, drugs of abuse, or toxin exposure.

[0004] Bipolar Disorder is associated with a significant risk of completed suicide. Further, the patient suffering from Bipolar Disorder is likely to suffer from school truancy, school failure, occupational failure, or divorce.

[0005] Therefore, Bipolar Disorder is a serious, fairly prevalent, psychological condition which is clearly distinguished from psychotic conditions such as schizophrenia. DSM-IV, p. 353 (American Psychiatric Association, Washington, D.C. 1994).

[0006] There remains a long felt need for treatments which provide a favorable safety profile and effectively provide relief for the patient suffering from Bipolar Disorder.

[0007] The invention provides a method for treating a patient suffering from or susceptible to Bipolar Disorder, Bipolar Depression or Unipolar Depression with or without psychotic features comprising administering to said patient an effective amount of a first component which is an atypical antipsychotic, in combination with an effective amount of a second component which is selected from the group consisting of a serotonin reuptake inhibitor, an anticonvulsant and lithium.

[0008] As used herein, the term "Bipolar Disorder" shall refer to a condition characterized as a Bipolar Disorder, in the DSM-IV-R. Diagnostic and Statistical Manual of Mental Disorders, Revised, 3rd Ed. (1994) as category 296.xx. To further clarify, Applicants contemplate the treatment of both Bipolar Disorder I and Bipolar disorder II as described in the DSM-IV-R. The DSM-IV-R was prepared by the Task Force on Nomenclature and Statistics of the American Psychiatric Association, and provides clear descriptions of diagnostic categories. The skilled artisan will recognize that there are alternative nomenclatures, nosologies, and classification systems for pathologic psychological conditions and that these systems evolve with medical scientific progress.

[0009] In this document, all temperatures are described in degrees Celsius, and all amounts, ratios of amounts and concentrations are described in weight units unless otherwise stated.

[0010] As used herein, the term "mammal" shall refer to the Mammalia class of higher vertebrates. The term "mammal" includes, but is not limited to, a human. The term "treating" as used herein includes prophylaxis of the named condition or amelioration or elimination of the condition once it has been established.

## The Compounds

[0011] In the general expressions of the present invention, the first component is a compound which acts as an atypical antipsychotic. The essential feature of an atypical antipsychotic is less acute extrapyramidal symptoms, especially dystonias, associated with therapy as compared to a typical antipsychotic such as haloperidol. Clozapine, the prototypical atypical antipsychotic, differs from the typical antipsychotics with the following characteristics: (1) greater efficacy in the treatment of overall psychopathology in patients with schizophrenia nonresponsive to typical antipsychotics; (2) greater efficacy in the treatment of negative symptoms of schizophrenia; and (3) less frequent and quantitatively smaller increases in serum prolactin concentrations associated with therapy (Beasley, et al., Neuropsychopharmacology, 14(2), 111-123. (1996)). Atypical antipsychotics include, but are not limited to:

Olanzapine, 2-methyl-4-(4-methyl-1-piperazinyl)-10H-thieno[2,3-b][1,5]benzodiazepine, is a known compound and is described in U.S. Patent No. 5,229,382 as being useful for the treatment of schizophrenia, schizophreniform disorder, acute mania, mild anxiety states, and psychosis. U.S. Patent No. 5,229,382 is herein incorporated by reference in its entirety;

Clozapine, 8-chloro-11-(4-methyl-1-piperazinyl)-5H-dibenzo[b,e][1,4]diazepine, is described in U.S. Patent No. 3,539,573, which is herein incorporated by reference in its entirety. Clinical efficacy in the treatment of schizophrenia is described (Hanes, et al., Psychopharmacol. Bull., 24, 62 (1988));

Risperidone, 3-[2-[4-(6-fluoro-1,2-benzisoxazol-3-yl)piperidino]ethyl]-2-methyl-6,7,8,9-tetrahydro-4H-pyrido-[1,2-a]pyrimidin-4-one, and its use in the treatment of psychotic diseases are described in U.S. Patent No. 4,804,663, which is herein incorporated by reference in its entirety;

Sertindole, 1-[2-[4-[5-chloro-1-(4-fluorophenyl)-1H-indol-3-yl]-1-piperidinyl]ethyl]imidazolidin-2-one, is described in U.S. Patent No. 4,710,500. Its use in the treatment of schizophrenia is described in U.S. Patent Nos. 5,112,838 and 5,238,945. U.S. Patent Nos. 4,710,500; 5,112,838; and 5,238,945 are herein incorporated by reference in their entirety;

Quetiapine, 5-[2-(4-dibenzo[b,f][1,4]thiazepin-11-yl-1-piperazinyl)ethoxy]ethanol, and its activity in assays which demonstrate utility in the treatment of schizophrenia are described in U.S. Patent No. 4,879,288, which is herein incorporated by reference in its entirety. Quetiapine is typically administered as its (E)-2-butenedioate (2:1) salt; and Ziprasidone, 5-[2-[4-(1,2-benzisothiazol-3-yl)-1-piperazinyl]ethyl]-6-chloro-1,3-dihydro-2H-indol-2-one, is typically administered as the hydrochloride monohydrate. The compound is described in U.S. Patent Nos. 4,831,031 and 5,312,925. Its activity in assays which demonstrate utility in the treatment of schizophrenia are described in U.S. Patent No. 4,831,031. U.S. Patent Nos. 4,831,031 and 5,312,925 are herein incorporated by reference in their entirety.

[0012] Similarly, when the invention is regarded in its broadest sense, the second component compound is a compound which functions as a serotonin reuptake inhibitor, an anticonvulsant or lithium. The measurement of a compound's activity as an SSRI is now a standard pharmacological assay. Wong, et al., *Neuropsychopharmacology* 8, 337-344 (1993). Many compounds, including those discussed at length above, have such activity, and no doubt many more will be identified in the future. In the practice of the present invention, it is intended to include reuptake inhibitors which show 50% effective concentrations of about 1000 nM or less, in the protocol described by Wong *supra*. Serotonin reuptake inhibitors include, but are not limited to:

Fluoxetine, N-methyl-3-(p-trifluoromethylphenoxy)-3-phenylpropylamine, is marketed in the hydrochloride salt form, and as the racemic mixture of its two enantiomers. U.S. Patent 4,314,081 is an early reference on the compound. Robertson et al., *J. Med. Chem.* 31, 1412 (1988), taught the separation of the R and S enantiomers of fluoxetine and showed that their activity as serotonin uptake inhibitors is similar to each other. In this document, the word "fluoxetine" will be used to mean any acid addition salt or the free base, and to include either the racemic mixture or either of the R and S enantiomers;

Duloxetine, N-methyl-3-(1-naphthalenyloxy)-3-(2-thienyl)propanamine, is usually administered as the hydrochloride salt and as the (+) enantiomer. It was first taught by U.S. Patent 4,956,388, which shows its high potency. The word "duloxetine" will be used here to refer to any acid addition salt or the free base of the molecule;

Venlafaxine is known in the literature, and its method of synthesis and its activity as an inhibitor of serotonin and norepinephrine uptake are taught by U.S. Patent 4,761,501. Venlafaxine is identified as compound A in that patent; Milnacipran (N,N-diethyl-2-aminomethyl-1-phenylcyclopropanecarboxamide) is taught by U.S. Patent 4,478,836, which prepared milnacipran as its Example 4. The patent describes its compounds as antidepressants. Moret et al., *Neuropharmacology* 24, 1211-19 (1985), describe its pharmacological activities as an inhibitor of serotonin and norepinephrine reuptake;

Citalopram, 1-[3-(dimethylamino)propyl]-1-(4-fluorophenyl)-1,3-dihydro-5-isobenzofurancarbonitrile, is disclosed in U.S. Patent 4,136,193 as a serotonin reuptake inhibitor. Its pharmacology was disclosed by Christensen et al., *Eur. J. Pharmacol.* 41, 153 (1977), and reports of its clinical effectiveness in depression may be found in Dufour et al., *Int. Clin. Psychopharmacol.* 2, 225 (1987), and Timmerman et al., *ibid.*, 239;

Fluvoxamine, 5-methoxy-1-[4-(trifluoromethyl)-phenyl]-1-pentanone O-(2-aminooethyl)oxime, is taught by U.S. Patent 4,085,225. Scientific articles about the drug have been published by Claassen et al., *Brit. J. Pharmacol.* 60, 505 (1977); and De Wilde et al., *J. Affective Disord.* 4, 249 (1982); and Benfield et al., *Drugs* 32, 313 (1986);

Paroxetine, trans-(-)-3-[(1,3-benzodioxol-5-yloxy)methyl]-4-(4-fluorophenyl)piperidine, may be found in U.S. Patents 3,912,743 and 4,007,196. Reports of the drug's activity are in Lassen, *Eur. J. Pharmacol.* 47, 351 (1978); Hassan et al., *Brit. J. Clin. Pharmacol.* 19, 705 (1985); Laursen et al., *Acta Psychiat. Scand.* 71, 249 (1985); and Battagay et al., *Neuropsychobiology* 13, 31 (1985);

Sertraline, (1S-cis)-4-(3,4-dichlorophenyl)-1,2,3,4-tetrahydro-N-methyl-1-naphthylamine hydrochloride, is a serotonin reuptake inhibitor which is marketed as an antidepressant. It is disclosed by U.S. Patent 4,536,518;

Anticonvulsants contemplated as the second component include, but are not limited to, carbamazepine, valproic acid, lamotrigine, gabapentin and topiramate;

Carbamazepine, 5H-dibenz[b,f]azepine-5-carboxamide is an anticonvulsant and analgesic marketed for trigeminal neuralgia; U.S. Patent 2,948,718 (herein incorporated by reference in its entirety), discloses carbamazepine and methods of use;

Valproic Acid, 2-propylpentanoic acid or dispropylacetic acid is a well known antiepileptic agent which dissociates

to the valproate ion in the gastrointestinal tract; various pharmaceutically acceptable salts are disclosed in U.S. Patent 4,699,927.

Lamotrigine, 6-(2,3-dichlorophenyl)-1,2,4-triazine-3,5-diamine is an antiepileptic drug indicated as adjunctive therapy in the treatment of partial seizures in adults with epilepsy. Lamotrigine and its uses is disclosed in U.S. Patent 4,486,354, herein incorporated by reference in its entirety;

Gabapentin, 1-(aminomethyl)cyclohexane acetic acid, is an anticonvulsant indicated as adjunctive therapy in the treatment of partial seizures with and without secondary generalization in adults with epilepsy. Gabapentin and its methods of use is described in U.S. Patents 4,024,175 and 4,087,544 herein incorporated by reference in their entirety;

Topiramate, 2,3,4,5-di-O-(1-isopropylidene)-3-D-fructopyranose sulphamate is an antiepileptic indicated for the treatment of refractory partial seizures, with or without secondary generalization and disclosed in U.S. Patent 4,513,006 herein incorporated by reference in its entirety; and

Lithium, preferably lithium carbonate, is indicated in the treatment of manic episodes of manic depressive illness.

**[0013]** All of the U.S. patents which have been mentioned above in connection with compounds used in the present invention are incorporated herein by reference.

**[0014]** It will be understood that while the use of a single atypical antipsychotic as a first component compound is preferred, combinations of two or more atypical antipsychotics may be used as a first component if necessary or desired. Similarly, while the use of a single serotonin reuptake inhibitor as a second component compound is preferred, combinations of two or more serotonin reuptake inhibitors may be used as a second component if necessary or desired.

**[0015]** While all combinations of first and second component compounds are useful and valuable, certain combinations are particularly valued and are preferred, as follows:

olanzapine/fluoxetine  
olanzapine/venlafaxine  
olanzapine/citalopram  
olanzapine/fluvoxamine  
olanzapine/paroxetine  
olanzapine/sertraline  
olanzapine/milnacipran  
olanzapine/duloxetine  
clozapine/fluoxetine  
risperidone/fluoxetine  
sertindole/fluoxetine  
quetiapine/fluoxetine  
ziprasidone/fluoxetine

**[0016]** In general, combinations and methods of treatment using olanzapine as the first component are preferred. Furthermore, combinations and methods of treatment using fluoxetine as the second component are preferred. Especially preferred are combinations and methods of treatment using olanzapine as the first component and fluoxetine as the second component.

**[0017]** It is especially preferred that when the first component is olanzapine, it will be the Form II olanzapine polymorph having a typical x-ray powder diffraction pattern as represented by the following interplanar spacings:

d

10.2689  
8.577  
7.4721  
7.125  
6.1459  
6.071  
5.4849  
5.2181  
5.1251  
4.9874  
4.7665

EP 0 966 967 A2

(continued)

	d	4.7158
5		4.4787
		4.3307
		4.2294
		4.141
10		3.9873
		3.7206
		3.5645
		3.5366
		3.3828
15		3.2516
		3.134
		3.0848
		3.0638
		3.0111
20		2.8739
		2.8102
		2.7217
		2.6432
25		2.6007

[0018] A typical example of an x-ray diffraction pattern for Form II is as follows wherein d represents the interplanar spacing and I/I<sub>1</sub> represents the typical relative intensities:

30	d	I/I <sub>1</sub>
	10.2689	100.00
	8.577	7.96
	7.4721	1.41
35	7.125	6.50
	6.1459	3.12
	6.071	5.12
	5.4849	0.52
	5.2181	6.86
40	5.1251	2.47
	4.9874	7.41
	4.7665	4.03
	4.7158	6.80
45	4.4787	14.72
	4.3307	1.48
	4.2294	23.19
	4.141	11.28
	3.9873	9.01
50	3.7206	14.04
	3.5645	2.27
	3.5366	4.85
	3.3828	3.47
	3.2516	1.25
55	3.134	0.81
	3.0848	0.45

(continued)

d	I/I <sub>1</sub>
3.0638	1.34
3.0111	3.51
2.8739	0.79
2.8102	1.47
2.7217	0.20
2.6432	1.26
2.6007	0.77

[0019] The x-ray diffraction patterns set out herein were obtained using a Siemens D5000 x-ray powder diffractometer having a copper K<sub>α</sub> radiation source of wavelength,  $\lambda = 1.541 \text{ \AA}$ .

[0020] It is further preferred that the Form II olanzapine polymorph will be administered as the substantially pure Form II olanzapine polymorph.

[0021] As used herein "substantially pure" refers to Form II associated with less than about 5% Form I, preferably less than about 2% Form I, and more preferably less than about 1% Form I. Further, "substantially pure" Form II will contain less than about 0.5% related substances, wherein "related substances" refers to undesired chemical impurities or residual solvent or water. In particular, "substantially pure" Form II should contain less than about 0.05% content of acetonitrile, more preferably, less than about 0.005% content of acetonitrile. Additionally, the polymorph of the invention should contain less than 0.5% of associated water.

[0022] The polymorph obtainable by the process taught in the '382 patent will be designated as Form I and has a typical x-ray powder diffraction pattern substantially as follows, obtained using a Siemens D5000 x-ray powder diffractometer, wherein d represents the interplanar spacing:

d	9.9463
	8.5579
	8.2445
	6.8862
	6.3787
	6.2439
	5.5895
	5.3055
	4.9815
	4.8333
	4.7255
	4.6286
	4.533
	4.4624
	4.2915
	4.2346
	4.0855
	3.8254
	3.7489
	3.6983
	3.5817
	3.5064
	3.3392
	3.2806
	3.2138
	3.1118
	3.0507

(continued)

d

	2.948
5	2.8172
	2.7589
	2.6597
	2.6336
10	2.5956

[0023] A typical example of an x-ray diffraction pattern for Form I is as follows wherein d represents the interplanar spacing and I/I<sub>1</sub> represents the typical relative intensities:

	d	I/I <sub>1</sub>
15	9.9463	100.00
	8.5579	15.18
	8.2445	1.96
20	6.8862	14.73
	6.3787	4.25
	6.2439	5.21
	5.5895	1.10
	5.3055	0.95
25	4.9815	6.14
	4.8333	68.37
	4.7255	21.88
	4.6286	3.82
30	4.533	17.83
	4.4624	5.02
	4.2915	9.19
	4.2346	18.88
	4.0855	17.29
35	3.8254	6.49
	3.7489	10.64
	3.6983	14.65
	3.5817	3.04
	3.5064	9.23
40	3.3392	4.67
	3.2806	1.96
	3.2138	2.52
	3.1118	4.81
45	3.0507	1.96
	2.948	2.40
	2.8172	2.89
	2.7589	2.27
	2.6597	1.86
50	2.6336	1.10
	2.5956	1.73


[0024] The x-ray powder diffraction patterns herein were obtained with a copper K<sub>α</sub> of wavelength  $\lambda = 1.541\text{\AA}$ . The interplanar spacings in the column marked "d" are in Angstroms. The typical relative intensities are in the column marked "I/I<sub>1</sub>".

[0025] Though Form II olanzapine is preferred it will be understood that as used herein, the term "olanzapine" embraces all solvate and polymorphic forms unless specifically indicated.

**Preparation 1**

Technical Grade olanzapine

[0026]



Intermediate 1

[0027] In a suitable three neck flask the following was added:

Dimethylsulfoxide (analytical)	6 volumes
Intermediate 1	75 g
N-Methylpiperazine (reagent) equivalents	6

Intermediate 1 can be prepared using methods known to the skilled artisan. For example, the preparation of the Intermediate 1 is taught in the above-referenced '382 patent.

[0028] A sub-surface nitrogen sparge line was added to remove the ammonia formed during the reaction. The reaction was heated to 120°C and maintained at that temperature throughout the duration of the reaction. The reactions were followed by HPLC until = 5% of the intermediate 1 was left unreacted. After the reaction was complete, the mixture was allowed to cool slowly to 20°C (about 2 hours). The reaction mixture was then transferred to an appropriate three neck round bottom flask and water bath. To this solution with agitation was added 10 volumes reagent grade methanol and the reaction was stirred at 20°C for 30 minutes. Three volumes of water was added slowly over about 30 minutes. The reaction slurry was cooled to zero to 5°C and stirred for 30 minutes. The product was filtered and the wet cake was washed with chilled methanol. The wet cake was dried in vacuo at 45°C overnight. The product was identified as technical olanzapine.

Yield: 76.7%; Potency: 98.1%

**Preparation 2**

Form II olanzapine polymorph

[0029] A 270 g sample of technical grade 2-methyl-4-(4-methyl-1-piperazinyl)-10H-thieno[2,3-b][1,5]benzodiazepine was suspended in anhydrous ethyl acetate (2.7 L). The mixture was heated to 76°C and maintained at 76°C for 30 minutes. The mixture was allowed to cool to 25°C. The resulting product was isolated using vacuum filtration. The product was identified as Form II using x-ray powder analysis.

Yield: 197 g.

[0030] The process described above for preparing Form II provides a pharmaceutically elegant product having potency ≥ 97%, total related substances < 0.5% and an isolated yield of > 73%.

[0031] It will be understood by the skilled reader that most or all of the compounds used in the present invention are capable of forming salts, and that the salt forms of pharmaceuticals are commonly used, often because they are more readily crystallized and purified than are the free bases. In all cases, the use of the pharmaceuticals described above



as salts is contemplated in the description herein, and often is preferred, and the pharmaceutically acceptable salts of all of the compounds are included in the names of them.

[0032] Many of the compounds used in this invention are amines, and accordingly react with any of a number of inorganic and organic acids to form pharmaceutically acceptable acid addition salts. Since some of the free amines of the compounds of this invention are typically oils at room temperature, it is preferable to convert the free amines to their pharmaceutically acceptable acid addition salts for ease of handling and administration, since the latter are routinely solid at room temperature. Acids commonly employed to form such salts are inorganic acids such as hydrochloric acid, hydrobromic acid, hydroiodic acid, sulfuric acid, phosphoric acid, and the like, and organic acids, such as p-toluenesulfonic acid, methanesulfonic acid, oxalic acid, p-bromophenylsulfonic acid, carbonic acid, succinic acid, citric acid, benzoic acid, acetic acid and the like. Examples of such pharmaceutically acceptable salts thus are the sulfate, pyrosulfate, bisulfate, sulfite, bisulfite, phosphate, monohydrogenphosphate, dihydrogenphosphate, metaphosphate, pyrophosphate, chloride, bromide, iodide, acetate, propionate, decanoate, caprylate, acrylate, formate, isobutyrate, caproate, heptanoate, propiolate, oxalate, malonate, succinate, suberate, sebacate, fumarate, maleate, butyne-1,4-dioate, hexyne-1,6-dioate, benzoate, chlorobenzoate, methylbenzoate, dinitrobenzoate, hydroxybenzoate, methoxybenzoate, phthalate, sulfonate, xylenesulfonate, phenylacetate, phenylpropionate, phenylbutyrate, citrate, lactate, b-hydroxybutyrate, glycollate, tartrate, methanesulfonate, propanesulfonate, naphthalene-1-sulfonate, naphthalene-2-sulfonate, mandelate and the like. Preferred pharmaceutically acceptable salts are those formed with hydrochloric acid, oxalic acid or fumaric acid.

## 20 Administration

[0033] The dosages of the drugs used in the present invention must, in the final analysis, be set by the physician in charge of the case, using knowledge of the drugs, the properties of the drugs in combination as determined in clinical trials, and the characteristics of the patient, including diseases other than that for which the physician is treating the patient. General outlines of the dosages, and some preferred dosages, can and will be provided here. Dosage guidelines for some of the drugs will first be given separately; in order to create a guideline for any desired combination, one would choose the guidelines for each of the component drugs.

Olanzapine: from about 0.25 to 100 mg, once/day; preferred, from 1 to 30 mg, once/day; and most preferably 1 to 25 mg once/day;  
 Clozapine: from about 12.5 to 900 mg daily; preferred, from about 150 to 450 mg daily;  
 Risperidone: from about 0.25 to 16 mg daily; preferred from about 2-8 mg daily;  
 Sertindole: from about .0001 to 1.0 mg/kg daily;  
 Quetiapine: from about 1.0 to 40 mg/kg given once daily or in divided doses;  
 Ziprasidone: from about 5 to 500 mg daily; preferred from about 50 to 100 mg daily;  
 Fluoxetine: from about 1 to about 80 mg, once/day; preferred, from about 10 to about 40 mg once/day; preferred for bulimia and obsessive-compulsive disease, from about 20 to about 80 mg once/day;  
 Duloxetine: from about 1 to about 160 mg once/day; or up to 80 mg twice daily; preferred, from about 5 to about 20 mg once/day;  
 Venlafaxine: from about 10 to about 150 mg once-thrice/day; preferred, from about 25 to about 125 mg thrice/day;  
 Milnacipran: from about 10 to about 100 mg once-twice/day; preferred, from about 25 to about 50 mg twice/day;  
 Citalopram: from about 5 to about 50 mg once/day; preferred, from about 10 to about 30 mg once/day;  
 Fluvoxamine: from about 20 to about 500 mg once/day; preferred, from about 50 to about 300 mg once/day;  
 Paroxetine: from about 20 to about 50 mg once/day; preferred, from about 20 to about 30 mg once/day;  
 Sertraline: from about 20 to about 500 mg once/day; preferred, from about 50 to about 200 mg once/day;  
 Lithium: from about 600 to 2100 mg/day; preferably 1200 mg/day;  
 Carbamazepine: from about 200 to 1200 mg/day; preferably 400 mg/day;  
 Valproic Acid: from about 250 to 2500 mg/day; preferably 1000 mg/day;  
 Lamotrigine: from about 50 to 600mg/day in 1 to 2 doses; preferably 200 to 400 mg; most preferably 200 mg;  
 Gabapentin: from about 300 to 3600 mg/day in 2 to 3 divided doses; preferably 300 to 1800 mg/day; most preferably 900 mg/day;  
 Topiramate: from about 200 to 600 mg/day divided in 2 doses; most preferably 400 mg/day.

[0034] In more general terms, one would create a combination of the present invention by choosing a dosage of first and second component compounds according to the spirit of the above guideline.

[0035] Preferred ratios of olanzapine/fluoxetine by weight include:

1/5	olanzapine: fluoxetine
6/25	
12.5/25	
25/50	
17.5/50	
25/75	

5

10 **[0036]** The adjunctive therapy of the present invention is carried out by administering a first component together with the second component in any manner which provides effective levels of the compounds in the body at the same time. All of the compounds concerned are orally available and are normally administered orally, and so oral administration of the adjunctive combination is preferred. They may be administered together, in a single dosage form, or may be administered separately.

15 **[0037]** However, oral administration is not the only route or even the only preferred route. For example, transdermal administration may be very desirable for patients who are forgetful or petulant about taking oral medicine. One of the drugs may be administered by one route, such as oral, and the others may be administered by the transdermal, percutaneous, intravenous, intramuscular, intranasal or intrarectal route, in particular circumstances. The route of administration may be varied in any way, limited by the physical properties of the drugs and the convenience of the patient and the caregiver.

20 **[0038]** The adjunctive combination may be administered as a single pharmaceutical composition, and so pharmaceutical compositions incorporating both compounds are important embodiments of the present invention. Such compositions may take any physical form which is pharmaceutically acceptable, but orally usable pharmaceutical compositions are particularly preferred. Such adjunctive pharmaceutical compositions contain an effective amount of each of the compounds, which effective amount is related to the daily dose of the compounds to be administered. Each adjunctive dosage unit may contain the daily doses of all compounds, or may contain a fraction of the daily doses, such as one-third of the doses. Alternatively, each dosage unit may contain the entire dose of one of the compounds, and a fraction of the dose of the other compounds. In such case, the patient would daily take one of the combination dosage units, and one or more units containing only the other compounds. The amounts of each drug to be contained in each dosage unit depends on the identity of the drugs chosen for the therapy, and other factors such as the indication for which the adjunctive therapy is being given.

30 **[0039]** The inert ingredients and manner of formulation of the adjunctive pharmaceutical compositions are conventional, except for the presence of the combination of the present invention. The usual methods of formulation used in pharmaceutical science may be used here. All of the usual types of compositions may be used, including tablets, chewable tablets, capsules, solutions, parenteral solutions, intranasal sprays or powders, troches, suppositories, transdermal patches and suspensions. In general, compositions contain from about 0.5% to about 50% of the compounds in total, depending on the desired doses and the type of composition to be used. The amount of the compounds, however, is best defined as the effective amount, that is, the amount of each compound which provides the desired dose to the patient in need of such treatment. The activity of the adjunctive combinations do not depend on the nature of the composition, so the compositions are chosen and formulated solely for convenience and economy. Any of the combinations may be formulated in any desired form of composition. Some discussion of different compositions will be provided, followed by some typical formulations.

35 **[0040]** Capsules are prepared by mixing the compound with a suitable diluent and filling the proper amount of the mixture in capsules. The usual diluents include inert powdered substances such as starch of many different kinds, powdered cellulose, especially crystalline and microcrystalline cellulose, sugars such as fructose, mannitol and sucrose, grain flours and similar edible powders.

40 **[0041]** Tablets are prepared by direct compression, by wet granulation, or by dry granulation. Their formulations usually incorporate diluents, binders, lubricants and disintegrators as well as the compound. Typical diluents include, for example, various types of starch, lactose, mannitol, kaolin, calcium phosphate or sulfate, inorganic salts such as sodium chloride and powdered sugar. Powdered cellulose derivatives are also useful. Typical tablet binders are substances such as starch, gelatin and sugars such as lactose, fructose, glucose and the like. Natural and synthetic gums are also convenient, including acacia, alginates, methylcellulose, polyvinylpyrrolidone and the like. Polyethylene glycol, ethylcellulose and waxes can also serve as binders.

50 **[0042]** A lubricant is necessary in a tablet formulation to prevent the tablet and punches from sticking in the die. The lubricant is chosen from such slippery solids as talc, magnesium and calcium stearate, stearic acid and hydrogenated vegetable oils.

55 **[0043]** Tablet disintegrators are substances which swell when wetted to break up the tablet and release the compound. They include starches, clays, celluloses, alginates and gums. More particularly, corn and potato starches, meth-

ylcellulose, agar, bentonite, wood cellulose, powdered natural sponge, cation-exchange resins, alginic acid, guar gum, citrus pulp and carboxymethylcellulose, for example, may be used, as well as sodium lauryl sulfate.

[0044] Enteric formulations are often used to protect an active ingredient from the strongly acid contents of the stomach. Such formulations are created by coating a solid dosage form with a film of a polymer which is insoluble in acid environments, and soluble in basic environments. Exemplary films are cellulose acetate phthalate, polyvinyl acetate phthalate, hydroxypropyl methylcellulose phthalate and hydroxypropyl methylcellulose acetate succinate. It is preferred to formulate duloxetine and duloxetine-containing combinations as enteric compositions, and even more preferred to formulate them as enteric pellets.

[0045] A preferred duloxetine enteric formulation is a pellet formulation comprising a) a core consisting of duloxetine and a pharmaceutically acceptable excipient; b) an optional separating layer; c) an enteric layer comprising hydroxypropylmethylcellulose acetate succinate (HPMCAS) and a pharmaceutically acceptable excipient; d) an optional finishing layer. This enteric formulation is described in U.S. Patent No. 5,508,276, herein incorporated by reference in its entirety.

[0046] Tablets are often coated with sugar as a flavor and sealant. The compounds may also be formulated as chewable tablets, by using large amounts of pleasant-tasting substances such as mannitol in the formulation, as is now well-established practice. Instantly dissolving tablet-like formulations are also now frequently used to assure that the patient consumes the dosage form, and to avoid the difficulty in swallowing solid objects that bothers some patients.

[0047] When it is desired to administer the combination as a suppository, the usual bases may be used. Cocoa butter is a traditional suppository base, which may be modified by addition of waxes to raise its melting point slightly. Water-miscible suppository bases comprising, particularly, polyethylene glycols of various molecular weights are in wide use, also.

[0048] Transdermal patches have become popular recently. Typically they comprise a resinous composition in which the drugs will dissolve, or partially dissolve, which is held in contact with the skin by a film which protects the composition. Many patents have appeared in the field recently. Other, more complicated patch compositions are also in use, particularly those having a membrane pierced with innumerable pores through which the drugs are pumped by osmotic action.

[0049] The following typical formulae are provided for the interest and information of the pharmaceutical scientist.

#### Formulation 1

[0050] Hard gelatin capsules are prepared using the following ingredients:

	Quantity (mg/capsule)
Olanzapine	25 mg
Fluoxetine, racemic, hydrochloride	20
Starch, dried	150
Magnesium stearate	10
Total	210 mg

#### Formulation 2

[0051] A tablet is prepared using the ingredients below:

	Quantity (mg/capsule)
Olanzapine	10
Fluoxetine, racemic, hydrochloride	10
Cellulose, microcrystalline	275
Silicon dioxide, fumed	10
Stearic acid	5
Total	310 mg

The components are blended and compressed to form tablets each weighing 465 mg.

Formulation 3

[0052] An aerosol solution is prepared containing the following components:

	Weight
Risperidone	5 mg
(+)-Duloxetine, hydrochloride	10
Ethanol	25.75
Propellant 22 (Chlorodifluoromethane)	60.00
Total	100.75 mg

[0053] The active compound is mixed with ethanol and the mixture added to a portion of the propellant 22, cooled to -30°C and transferred to a filling device. The required amount is then fed to a stainless steel container and diluted with the remainder of the propellant. The valve units are then fitted to the container.

Formulation 4

[0054] Tablets, each containing 80 mg of active ingredient, are made as follows:

Sertindole	60 mg
(+)-Duloxetine, hydrochloride	20 mg
Starch	30 mg
Microcrystalline cellulose	20 mg
Polyvinylpyrrolidone (as 10% solution in water)	4 mg
Sodium carboxymethyl starch	4.5 mg
Magnesium stearate	0.5 mg
Talc	1 mg
Total	140 mg

[0055] The active ingredient, starch and cellulose are passed through a No. 45 mesh U.S. sieve and mixed thoroughly. The aqueous solution containing polyvinylpyrrolidone is mixed with the resultant powder, and the mixture then is passed through a No. 14 mesh U.S. sieve. The granules so produced are dried at 50°C and passed through a No. 18 mesh U.S. Sieve. The sodium carboxymethyl starch, magnesium stearate and talc, previously passed through a No. 60 mesh U.S. sieve, are then added to the granules which, after mixing, are compressed on a tablet machine to yield tablets each weighing 170 mg.

Formulation 5

[0056] Capsules, each containing 130 mg of active ingredient, are made as follows:

Quetiapine	70 mg
Fluoxetine, racemic, hydrochloride	30 mg
Starch	39 mg
Microcrystalline cellulose	39 mg
Magnesium stearate	2 mg
Total	180 mg

[0057] The active ingredient, cellulose, starch, and magnesium stearate are blended, passed through a No. 45 mesh U.S. sieve, and filled into hard gelatin capsules in 250 mg quantities.

Formulation 6

[0058] Suppositories, each containing 45 mg of active ingredient, are made as follows:

Ziprasidone	75 mg
(+)-Duloxetine, hydrochloride	5 mg
Saturated fatty acid glycerides	2,000 mg
Total	2,080 mg

[0059] The active ingredient is passed through a No. 60 mesh U.S. sieve and suspended in the saturated fatty acid glycerides previously melted using the minimum heat necessary. The mixture is then poured into a suppository mold of nominal 2 g capacity and allowed to cool.

#### Formulation 7

[0060] Suspensions, each containing 70 mg of active ingredient per 5 ml dose, are made as follows:

Olanzapine	20 mg
Sertraline	100 mg
Sodium carboxymethyl cellulose	50 mg
Syrup	1.25 ml
Benzoic acid solution	0.10 ml
Flavor	q.v.
Color	q.v.
Purified water to total	5 ml

[0061] The active ingredient is passed through a No. 45 mesh U.S. sieve and mixed with the sodium carboxymethyl cellulose and syrup to form a smooth paste. The benzoic acid solution, flavor and color are diluted with a portion of the water and added, with stirring. Sufficient water is then added to produce the required volume.

#### Formulation 8

[0062] An intravenous formulation may be prepared as follows:

Olanzapine	20 mg
Paroxetine	25 mg
Isotonic saline	1,000 ml

#### Microdialysis assays of monoamines

[0063] Sprague-Dawley rats (Harlan or Charles River) weighing 270-300 grams are surgically implanted with microdialysis probes under chloral hydrate/pentobarbital anesthesia (170 and 36 mg/kg i.p. in 30% propylene glycol, 14% ethanol) (Perry and Fuller, Effect of fluoxetine on serotonin and dopamine concentration in rat hypothalamus after administration of fluoxetine plus L-5-hydroxytryptophan, *Life Sci.*, 50, 1683-90 (1992)). A David Kopf stereotaxic instrument is used to implant the probe unilaterally in the hypothalamus at coordinates rostral -1.5 mm, lateral -1.3 mm, and ventral -9.0 mm (Paxinos and Watson, 1986). After a 48 hour recovery period, rats are placed in a large plastic bowl with a mounted liquid swivel system (CMA/120 system for freely moving animals, Bioanalytical Systems, West Lafayette, IN). Filtered artificial cerebrospinal fluid (CSF) (150 mM NaCl, 3.0 mM KCl, 1.7 mM CaCl<sub>2</sub>, and 0.9 mM MgCl<sub>2</sub>) is perfused through the probe at a rate of 1.0 ml/min. The output dialysate line is fitted to a tenport HPLC valve with a 20 ml loop. At the end of each 30 minute sampling period, dialysate collected in the loop is injected on an analytical column (Spherisorb 3 μm ODS2, 2X150 mm, Keystone Scientific).

[0064] The method used to measure monoamines is as described by Perry and Fuller (1992). Briefly, dialysate collected in the 20 ml loop is assayed for 5-HT, NE and DA. The 20 ml injection goes onto the column with a mobile phase which resolves NE, DA, and 5-HT: 75 mM potassium acetate, 0.5 mM ethylenediaminetetraacetic acid, 1.4 mM sodium octanesulfonic acid and 8% methanol, pH 4.9. The mobile phase for the amine column is delivered with a flow programmable pump at an initial flow rate of 0.2 ml/min increasing to 0.3 ml/min at 5 min then decreasing back to 0.2 ml/min at 26 min with a total run time of 30 min. Flow programming is used to elute the 5-HT within a 25 min time period. The electrochemical detector (EG&G, Model 400) for the amine column is set at a potential of 400 mV and a sensitivity

of 0.2 nA/V. Basal levels are measured for at least 90 minutes prior to drug administration. The drugs are prepared in filtered deionized water (volume 0.25-0.3 ml) for administration at the desired doses.

#### Clinical Trials

[0065] The usefulness of the compound for treating a Bipolar Disorder can be supported by the following studies as described.

Clinical observations.

[0066] A double-blind multicenter clinical trial is designed to assess the safety and efficacy of an atypical antipsychotic in combination with an SSRI, such as fluoxetine for treatment of Bipolar Disorder, Bipolar Depression or Unipolar Depression. Patients are randomized to an atypical antipsychotic, such as olanzapine, an SSRI, such as fluoxetine or an atypical antipsychotic plus an SSRI.

[0067] In one such study, an 8-week, double blind trial, 28 patients diagnosed with treatment-resistant major depression were randomized to one of three treatment arms: (1) fluoxetine (20-60 mg/day) and placebo; (2) olanzapine (5-20 mg/day) and placebo; or (3) fluoxetine plus olanzapine (20-60 mg/day and 5-20 mg/day, respectively). The efficacy of the treatment was monitored using the HAMD-21 (Hamilton M. *Journal of Neurology, Neurosurgery & Psychiatry*. 1960;23:56-62, and Hamilton M. *Development of a rating scale for primary depressive illness*. British Journal of Social and Clinical Psychology. 1967;6:278-296), Montgomery-Asberg Depression Rating Scale (MADRS) (Montgomery SA, Asberg M. *A new depression scale designed to be sensitive to change*. British Journal of Psychiatry. 1979;134:382-389), and the Clinical Global Impression (CGI) - Severity of Depression rating scale (Guy, W. *ECDEU Assessment Manual for Psychopharmacology*. Revised ed. US Dept of Health, Education and Welfare, Bethesda, MD. 1976). The olanzapine plus fluoxetine group experienced a greater improvement on the HAMD-21 total score than either of the monotherapy groups. Similar results were obtained using the CGI scale.

[0068] The antidepressant effect of olanzapine plus fluoxetine was evident within seven days of beginning the therapy. This is significantly earlier than is generally seen with a monotherapy using a serotonin uptake inhibitor alone, with no evidence of significant adverse interaction between the antipsychotic and the serotonin reuptake inhibitor.

#### Claims

1. A method for treating a patient suffering from or susceptible to Bipolar Disorder, Bipolar Depression or Unipolar Depression comprising administering to said patient an effective amount of a first component which is an atypical antipsychotic, in combination with an effective amount of a second component selected from the group consisting of a serotonin reuptake inhibitor, an anticonvulsant and lithium.
2. A method of **Claim 1** where the first component is chosen from the group consisting of olanzapine, clozapine, risperidone, sertindole, quetiapine, and ziprasidone; and the second component is selected from the group consisting of fluoxetine, venlafaxine, citalopram, fluvoxamine, paroxetine, sertraline, milnacipran and duloxetine.
3. A method of **Claim 1** wherein the first component compound is olanzapine.
4. A method of **Claim 2** wherein the second component compound is fluoxetine.
5. A method of **Claim 1** where administration of the compounds is oral.
6. A method of **Claim 1** wherein the Bipolar Disorder is Bipolar Disorder I.
7. A method of **Claim 1** wherein the Bipolar Disorder is Bipolar Disorder II.
8. A method of **Claim 1** wherein olanzapine is Form II olanzapine polymorph having a typical x-ray diffraction pattern as follows, wherein d represents the interplanar spacing:

d

10.2689  
8.577

(continued)


d

	7.4721
5	7.125
	6.1459
	6.071
	5.4849
10	5.2181
	5.1251
	4.9874
	4.7665
	4.7158
15	4.4787
	4.3307
	4.2294
	4.141
20	3.9873
	3.7206
	3.5645
	3.5366
	3.3828
25	3.2516
	3.134
	3.0848
	3.0638
30	3.0111
	2.8739
	2.8102
	2.7217
	2.6432
35	2.6007

9. A method of **Claim 1** wherein the effective amount of olanzapine is from about 1 mg to about 25 mg per day.
10. A method of **Claim 9** wherein the effective amount of olanzapine is from about 1 mg to about 20 mg per day.
11. A method of any one of **Claims 1 to 8** wherein the ratio of olanzapine to fluoxetine by weight is selected from the group consisting of 1/5, 6/25, 12.5/25, 25/50, 17.5/50 and 25/75.
12. A method of **Claim 1** where the first component is selected from the group consisting of olanzapine, clozapine, risperidone, sertindole, quetiapine and ziprasidone; and the second component is selected from the group consisting of lithium, carbamazepine, valproic acid, lamotrigine, gabapentin and topiramate.
13. The use of an effective amount of a first component which is an atypical antipsychotic, in combination with an effective amount of a second component selected from the group consisting of a serotonin reuptake inhibitor, an anticonvulsant and lithium, for the manufacture of a medicament for the treatment of bipolar disorder, bipolar depression or unipolar depression.
14. A pharmaceutical composition adapted for the treatment of a patient suffering from, or susceptible to bipolar disorder, bipolar depression or unipolar depression, comprising as the active ingredients a combination of an atypical antipsychotic and a second component selected from the group consisting of a serotonin reuptake inhibitor, an anticonvulsant and lithium.







Europäisches Patentamt  
European Patent Office  
Office européen des brevets



(11) **EP 0 966 967 A3**

(12) **EUROPEAN PATENT APPLICATION**

(88) Date of publication A3:  
31.05.2000 Bulletin 2000/22

(51) Int Cl.7: **A61K 31/55, A61K 31/135,  
A61K 33/00, A61K 31/19,  
A61K 31/195**

(43) Date of publication A2:  
29.12.1999 Bulletin 1999/52

(21) Application number: 99303968.4

(22) Date of filing: 21.05.1999

(84) Designated Contracting States:  
**AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU  
MC NL PT SE**  
Designated Extension States:  
**AL LT LV MK RO SI**

(72) Inventor: **Tollefson, Gary Dennis**  
**Indianapolis, Indiana 46236 (US)**

(74) Representative: **Hudson, Christopher Mark et al**  
**Eli Lilly and Company Limited,**  
**Lilly Research Centre,**  
**Erl Wood Manor**  
**Windlesham Surrey GU20 6PH (GB)**

(30) Priority: 29.05.1998 US 87126 P

(71) Applicant: **ELI LILLY AND COMPANY**  
**Indianapolis, Indiana 46285 (US)**

(54) **Combination therapy of olanzapine (zyprexa) and fluoxetine (prozac) for treatment of bipolar disorder**

(57) The invention provides methods and compositions for the treatment of Bipolar Disorder, Bipolar Depression or Unipolar Depression, all with or without psy-

chotic features. This method employs a compound having activity as an atypical antipsychotic and a serotonin reuptake inhibitor.

**EP 0 966 967 A3**



European Patent  
Office

## EUROPEAN SEARCH REPORT

Application Number  
EP 99 30 3968

DOCUMENTS CONSIDERED TO BE RELEVANT			
Category	Citation of document with indication, where appropriate, of relevant passages	Relevant to claim	CLASSIFICATION OF THE APPLICATION (Int.Cl.6)
X	EP 0 830 864 A (LILLY CO ELI) 25 March 1998 (1998-03-25)  * page 13, line 1-10; claims 1-4,8-13; example 2 *	1-7, 9-11,13, 14	A61K31/55 A61K31/135 A61K33/00 A61K31/19 A61K31/195
Y	WO 97 33577 A (LILLY CO ELI ; BEASLEY CHARLES M JR (US); TOLLEFSON GARY D (US)) 18 September 1997 (1997-09-18) * abstract *	1-7, 9-11,13, 14	
Y	WO 92 00103 A (BEECHAM GROUP PLC) 9 January 1992 (1992-01-09)  * page 2; claim 7 *	1-7, 9-11,13, 14	
Y	WO 97 35586 A (LILLY CO ELI) 2 October 1997 (1997-10-02)  * page 9; claims 15,16 *	1-7, 9-11,13, 14	
A	LINDSAY DEVANE C. ET AL: "1998 Guide to psychotropic drug interactions" GUIDE TO PSYCHOTROPIC DRUG INTERACTIONS, 1998, pages 1-39, XP002102289 * tables 6,23 *	1-14	TECHNICAL FIELDS SEARCHED (Int.Cl.6)  A61K
A	MAJERONI BA. ET AL: "The pharmacologic treatment of depression" PHARMACOLOGIC TREATMENT OF DEPRESSION, March 1998 (1998-03), pages 1-19, XP002102290 * table 2 *	1-14	
-The present search report has been drawn up for all claims			
Place of search <b>THE HAGUE</b>		Date of completion of the search <b>5 October 1999</b>	Examiner <b>Gonzalez Ramon, N</b>
CATEGORY OF CITED DOCUMENTS  X : particularly relevant if taken alone Y : particularly relevant if combined with another document of the same category A : technological background O : non-written disclosure P : intermediate document		T : theory or principle underlying the invention E : earlier patent document, but published on, or after the filing date D : document cited in the application L : document cited for other reasons  & : member of the same patent family, corresponding document	

EPC FORM 1533 03 82 (P/C01)



European Patent  
Office

Application Number  
EP 99 30 3968

**CLAIMS INCURRING FEES**

The present European patent application comprised at the time of filing more than ten claims.

- ☐ Only part of the claims have been paid within the prescribed time limit. The present European search report has been drawn up for the first ten claims and for those claims for which claims fees have been paid, namely claim(s):
- ☐ No claims fees have been paid within the prescribed time limit. The present European search report has been drawn up for the first ten claims.

**LACK OF UNITY OF INVENTION**

The Search Division considers that the present European patent application does not comply with the requirements of unity of invention and relates to several inventions or groups of inventions, namely:

see sheet B

- ☐ All further search fees have been paid within the fixed time limit. The present European search report has been drawn up for all claims.
- ☐ As all searchable claims could be searched without effort justifying an additional fee, the Search Division did not invite payment of any additional fee.
- ☐ Only part of the further search fees have been paid within the fixed time limit. The present European search report has been drawn up for those parts of the European patent application which relate to the inventions in respect of which search fees have been paid, namely claims:
- ☒ None of the further search fees have been paid within the fixed time limit. The present European search report has been drawn up for those parts of the European patent application which relate to the invention first mentioned in the claims, namely claims:

2, 4, 11 complete, 1, 3, 5-10, 13, 14 partially



European Patent  
Office

## EUROPEAN SEARCH REPORT

Application Number  
EP 99 30 3968

DOCUMENTS CONSIDERED TO BE RELEVANT			
Category	Citation of document with indication, where appropriate, of relevant passages	Relevant to claim	CLASSIFICATION OF THE APPLICATION (Int.Cl.6)
X	SHERMAN C.: "Atypical antipsychotic as adjunct for depression Tx" CLINICAL PSYCHIATRY NEWS, [Online] vol. 26, no. 8, 1998, pages 1-2, XP002115885 Retrieved from the Internet: <URL:www.medscape.com/IMNG/Cli.../1998/v26.n08/cpn2608.01.03.html> [retrieved on 1999-09-16] * the whole document *	1-7, 9-11,13, 14	TECHNICAL FIELDS SEARCHED (Int.Cl.6)
Y	NIDECKER A.: "Olanzapine may soothe schizophrenic's depression" CLINICAL PSYCHIATRY NEWS, [Online] vol. 26, no. 5, 1998, pages 12-14, XP002115886 Retrieved from the Internet: <URL:womenshealth.medscape.com.../1998/v26.n05/cpn2605.12.01.html> [retrieved on 1999-09-16] * paragraph [0015] *	1-7, 9-11,13, 14	
T	OYESAMI O. ET AL: "Hematologic side effects of psychotropics" PSYCHOSOMATICS, vol. 40, no. 5, September 1999 (1999-09), pages 414-421, XP002116147 * page 4167 - page 418; tables 4,5 *	1-14	
X,P	SHARMA V. ET AL: "Treatment of bipolar mixed state with olanzapine" JOURNAL OF PSYCHIATRY AND NEUROSCIENCE, vol. 24, no. 1, January 1999 (1999-01), pages 40-44, XP002116146 * page 6 *	1-7, 9-11,13, 14	
-----			
-The present search report has been drawn up for all claims			
Place of search <b>THE HAGUE</b>		Date of completion of the search <b>5 October 1999</b>	Examiner <b>Gonzalez Ramon, N</b>
<p><b>CATEGORY OF CITED DOCUMENTS</b></p> <p>X : particularly relevant if taken alone Y : particularly relevant if combined with another document of the same category A : technological background O : non-written disclosure P : intermediate document</p> <p>T : theory or principle underlying the invention E : earlier patent document, but published on, or after the filing date D : document cited in the application L : document cited for other reasons &amp; : member of the same patent family, corresponding document</p>			

EPO FORM 1503 03.82 (P04C01)



European Patent  
Office

LACK OF UNITY OF INVENTION  
SHEET B

Application Number  
EP 99 30 3968

The Search Division considers that the present European patent application does not comply with the requirements of unity of invention and relates to several inventions or groups of inventions, namely:

1. Claims: 2,4,11 complete, 1,3,5-10,13,14 partially

A method of treating bipolar disorder, bipolar depression or unipolar depression comprising a combination of atypical antipsychotic and serotonin reuptake inhibitor

2. Claims: 1,3,5-10,13,14 partially

A method of treating bipolar disorder, bipolar depression or unipolar depression comprising a combination of atypical antipsychotic and anticonvulsant

3. Claims: 1,3,5-10,13,14 partially

A method of treating bipolar disorder, bipolar depression or unipolar depression comprising a combination of atypical antipsychotic and lithium

ANNEX TO THE EUROPEAN SEARCH REPORT  
ON EUROPEAN PATENT APPLICATION NO.

EP 99 30 3968

This annex lists the patent family members relating to the patent documents cited in the above-mentioned European search report.  
The members are as contained in the European Patent Office EDP file on  
The European Patent Office is in no way liable for these particulars which are merely given for the purpose of information.

05-10-1999

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
EP 0830864 A	25-03-1998	AU 4411297 A	14-04-1998
		CN 1230886 A	06-10-1999
		CZ 9900987 A	15-12-1999
		NO 991381 A	22-03-1999
		PL 332481 A	13-09-1999
		WO 9811897 A	26-03-1998
WO 9733577 A	18-09-1997	AU 1330797 A	01-10-1997
		BR 9612548 A	20-07-1999
		CN 1213966 A	14-04-1999
		CZ 9802902 A	13-10-1999
		EP 0889725 A	13-01-1999
		NO 984189 A	11-09-1998
WO 9200103 A	09-01-1992	PL 328925 A	01-03-1999
		AU 8072691 A	23-01-1992
WO 9735586 A	02-10-1997	ZA 9104920 A	29-04-1992
		AU 2543097 A	17-10-1997
		BR 9708254 A	03-08-1999
		CA 2250187 A	02-10-1997
		CN 1219877 A	16-06-1999
		CZ 9802982 A	13-01-1999
		EP 0921802 A	16-06-1999
		NO 984431 A	19-11-1998
		PL 329211 A	15-03-1999
		US 5945416 A	31-08-1999

EPC FORM P0459

For more details about this annex see Official Journal of the European Patent Office, No. 12/82